1844 related articles for article (PubMed ID: 17252575)
41. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone.
Ghanem N; Uhl M; Brink I; Schäfer O; Kelly T; Moser E; Langer M
Eur J Radiol; 2005 Jul; 55(1):41-55. PubMed ID: 15950100
[TBL] [Abstract][Full Text] [Related]
43. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
44. F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.
von Falck C; Rodt T; Joerdens S; Waldeck S; Kiesel H; Knapp WH; Galanski M
Clin Nucl Med; 2009 Aug; 34(8):493-5. PubMed ID: 19617723
[TBL] [Abstract][Full Text] [Related]
45. Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection?
Hahn S; Bauer S; Heusner TA; Ebeling P; Hamami ME; Stahl A; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Dec; 80(3):670-4. PubMed ID: 20970938
[TBL] [Abstract][Full Text] [Related]
46. FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study.
Jager JJ; Keymeulen K; Beets-Tan RG; Hupperets P; van Kroonenburgh M; Houben R; de Ruysscher D; Lambin P; Boersma LJ
Acta Oncol; 2010; 49(2):185-91. PubMed ID: 20017664
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
48. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
49. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma.
Mertz HR; Sechopoulos P; Delbeke D; Leach SD
Gastrointest Endosc; 2000 Sep; 52(3):367-71. PubMed ID: 10968852
[TBL] [Abstract][Full Text] [Related]
50. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
51. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
[TBL] [Abstract][Full Text] [Related]
52. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
53. Does 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses.
Rubello D; Nanni C; Castellucci P; Rampin L; Farsad M; Franchi R; Mariani G; Menaldo G; Fanti S
Panminerva Med; 2005 Sep; 47(3):187-9. PubMed ID: 16462726
[TBL] [Abstract][Full Text] [Related]
54. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
55. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
[TBL] [Abstract][Full Text] [Related]
56. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer.
Hauth EA; Antoch G; Stattaus J; Kuehl H; Veit P; Bockisch A; Kimmig R; Forsting M
Eur J Radiol; 2005 Nov; 56(2):263-8. PubMed ID: 16233894
[TBL] [Abstract][Full Text] [Related]
58. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation.
Prytz H; Keiding S; Björnsson E; Broomé U; Almer S; Castedal M; Munk OL;
Hepatology; 2006 Dec; 44(6):1572-80. PubMed ID: 17133469
[TBL] [Abstract][Full Text] [Related]
59. Cardiac metastases of Ewing sarcoma detected by 18F-FDG PET/CT.
Coccia P; Ruggiero A; Rufini V; Maurizi P; Attinà G; Marano R; Natale L; Leccisotti L; Calcagni ML; Riccardi R
J Pediatr Hematol Oncol; 2012 Apr; 34(3):236-8. PubMed ID: 22395217
[TBL] [Abstract][Full Text] [Related]
60. Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer.
Fukunaga H; Sekimoto M; Ikeda M; Higuchi I; Yasui M; Seshimo I; Takayama O; Yamamoto H; Ohue M; Tatsumi M; Hatazawa J; Ikenaga M; Nishimura T; Monden M
Ann Surg Oncol; 2005 Jul; 12(7):561-9. PubMed ID: 15889211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
